AR061343A1 - Productos farmaceuticos uso de un antagonista de ccr5 - Google Patents

Productos farmaceuticos uso de un antagonista de ccr5

Info

Publication number
AR061343A1
AR061343A1 ARP070102549A ARP070102549A AR061343A1 AR 061343 A1 AR061343 A1 AR 061343A1 AR P070102549 A ARP070102549 A AR P070102549A AR P070102549 A ARP070102549 A AR P070102549A AR 061343 A1 AR061343 A1 AR 061343A1
Authority
AR
Argentina
Prior art keywords
ccr5 antagonist
hiv
pharmaceutical products
products use
patients
Prior art date
Application number
ARP070102549A
Other languages
English (en)
Inventor
Howard Bernard Mayer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR061343A1 publication Critical patent/AR061343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de un antagonista de CCR5 en un paciente infectado con VIH para mejorar su restitucion inmunitaria y así tratar las enfermedades oportunistas relacionadas con VIH resultantes del estado inmunocomprometido del paciente con VIH. La presente también permite el tratamiento con un antagonista de CCR5 de pacientes que tienen una poblacion vírica que usa CXCR4, ya que dichos pacientes también se beneficiarán de un aumento en su nivel de células CD4 y/o CD8.
ARP070102549A 2006-06-12 2007-06-11 Productos farmaceuticos uso de un antagonista de ccr5 AR061343A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80448006P 2006-06-12 2006-06-12
US82197406P 2006-08-12 2006-08-12
US88838707P 2007-02-06 2007-02-06

Publications (1)

Publication Number Publication Date
AR061343A1 true AR061343A1 (es) 2008-08-20

Family

ID=38832981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102549A AR061343A1 (es) 2006-06-12 2007-06-11 Productos farmaceuticos uso de un antagonista de ccr5

Country Status (13)

Country Link
US (1) US20090247570A1 (es)
EP (1) EP2043640A2 (es)
JP (1) JP2007332141A (es)
KR (1) KR20090013827A (es)
CN (1) CN101466376A (es)
AR (1) AR061343A1 (es)
AU (1) AU2007258907A1 (es)
BR (1) BRPI0712843A2 (es)
IL (1) IL195149A0 (es)
MX (1) MX2008014296A (es)
RU (1) RU2420284C2 (es)
WO (1) WO2007144720A2 (es)
ZA (1) ZA200809488B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065369A1 (es) 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
RU2516931C2 (ru) * 2010-08-06 2014-05-20 Олег Ильич Эпштейн Способ и композиция для профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
CA2839558A1 (en) * 2011-06-19 2012-12-27 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
CN109893644A (zh) 2011-06-19 2019-06-18 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
DK3393468T3 (da) 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Fremgangsmåder til behandling af en immundefektsygdom
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHODS OF TREATING CANCER
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223239A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
RU2715230C2 (ru) * 2017-04-25 2020-02-26 Бионорика Се Способ лечения орофарингеального кандидоза у вич-инфицированных пациентов на поздних стадиях заболевания
CA3089848A1 (en) * 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020051452A2 (en) * 2018-09-07 2020-03-12 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Hiv or hcv detection with crispr-cas13a
MX2022001411A (es) * 2019-08-02 2022-03-25 Cytodyn Inc Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US6667314B2 (en) * 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
US7393934B2 (en) * 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Also Published As

Publication number Publication date
JP2007332141A (ja) 2007-12-27
US20090247570A1 (en) 2009-10-01
IL195149A0 (en) 2009-09-22
AU2007258907A1 (en) 2007-12-21
WO2007144720A3 (en) 2008-10-23
ZA200809488B (en) 2010-01-27
KR20090013827A (ko) 2009-02-05
EP2043640A2 (en) 2009-04-08
BRPI0712843A2 (pt) 2012-07-31
WO2007144720A2 (en) 2007-12-21
RU2008146256A (ru) 2010-07-20
MX2008014296A (es) 2009-03-06
RU2420284C2 (ru) 2011-06-10
CN101466376A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
AR061343A1 (es) Productos farmaceuticos uso de un antagonista de ccr5
CO6460769A2 (es) Inhibidores de la replicación viral novedosos
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CL2013003298A1 (es) Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
BR112012029304A2 (pt) copolíme-ros em bloco de polissiloxano e seu uso em formulações cosmeticas
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
CL2012002743A1 (es) Combinación que comprende maraviroc, un inhibidor de proteasa de vih-1 y un potenciador famacocinetico, uso en la preparacion de un medicamento util en el tratmiento de infeccion por vih.
BRPI0514333A (pt) complexo compreendendo um amido e um ingrediente ativo anti-hiv-1 ou anti-hiv-2 do suco de romã, composição farmacêutica, e, método para a prevenção da infecção pelo hiv-1 ou pelo hiv-2 em um ser humano
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
IN2013CH05288A (es)
IN2014DN10408A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal